Pharmaceutical companies in the United States by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Viatris has the lowest figure of the 34 pharmaceutical companies in the United States ranked by P/S ratio, at 1.6, followed by Amneal Pharmaceuticals (2.4) and Pfizer (2.5). Figures as of 20 Nov 2026, 16:40 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 34
- Lowest
- Viatris1.6
- Median
- 7.9
- Combined market value
- CZK 83.87T
- Countries
- 1
- Not ranked
- 10no P/S ratio on file
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ViatrisVTRS · Health Care | 1.6 | CZK 498.3B | CZK 434.67 | 1.81% down | 90% up | ||
| 2 | Amneal PharmaceuticalsAMRX · Health Care | 2.4 | CZK 164.1B | CZK 470.97 | 1.12% down | 79% up | ||
| 3 | PfizerPFE · Health Care | 2.5 | CZK 3.51T | CZK 615.78 | 0.41% up | 10% up | ||
| 4 | Bristol-Myers SquibbBMY · Health Care | 2.5 | CZK 2.71T | CZK 1,324.72 | 1.97% up | 26% up | ||
| 5 | Elanco Animal HealthELAN · Health Care | 2.8 | CZK 289B | CZK 578.19 | 1.24% down | 18% up | ||
| 6 | PTC TherapeuticsPTCT · Health Care | 2.8 | CZK 107.3B | CZK 1,284.31 | 1.11% down | 26% down | ||
| 7 | Legend BiotechLEGN · Health Care | 2.9 | CZK 67.6B | CZK 348.27 | 2.86% down | 43% down | ||
| 8 | ZoetisZTS · Health Care | 3.5 | CZK 732.2B | CZK 1,802.15 | 0.17% up | 34% down | ||
| 9 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | CZK 263.5B | CZK 1,360.57 | 0.52% down | 12% up | ||
| 10 | Abbott LaboratoriesABT · Health Care | 4.1 | CZK 4.02T | CZK 2,319.43 | 0.28% up | 19% down | ||
| 11 | Ionis PharmaceuticalsIONS · Health Care | 4.9 | CZK 102.1B | CZK 613.04 | 1.14% up | 64% down | ||
| 12 | Merck & CoMRK · Health Care | 5.1 | CZK 7.42T | CZK 3,010.63 | 1.80% up | 36% up | ||
| 13 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | CZK 448.8B | CZK 3,350.44 | 1.79% up | 66% down | ||
| 14 | Regeneron PharmaceuticalsREGN · Health Care | 6.7 | CZK 2.15T | CZK 20,751.77 | 1.03% up | 22% up | ||
| 15 | Johnson & JohnsonJNJ · Health Care | 6.9 | CZK 14.54T | CZK 6,037.97 | 1.50% up | 31% up | ||
| 16 | Arrowhead PharmaceuticalsARWR · Health Care | 7.3 | CZK 135B | CZK 954.63 | 1.79% down | 8% up | ||
| 17 | United TherapeuticsUTHR · Health Care | 7.5 | CZK 528.6B | CZK 12,411.74 | 0.31% down | 18% up | ||
| 18 | AbbVieABBV · Health Care | 8.3 | CZK 11.35T | CZK 6,420.53 | 1.69% up | 20% up | ||
| 19 | Corcept TherapeuticsCORT · Health Care | 9.2 | CZK 155.4B | CZK 1,419.92 | 1.87% down | 16% down | ||
| 20 | Travere TherapeuticsTVTX · Health Care | 9.5 | CZK 103.5B | CZK 1,078.55 | 0.28% up | 39% up | ||
| 21 | Madrigal PharmaceuticalsMDGL · Health Care | 9.5 | CZK 202.2B | CZK 8,705.90 | 1.46% down | 28% down | ||
| 22 | Axsome TherapeuticsAXSM · Health Care | 10.7 | CZK 152.8B | CZK 2,904.42 | 3.87% down | 9% down | ||
| 23 | Vertex PharmaceuticalsVRTX · Health Care | 11.1 | CZK 2.97T | CZK 11,696.49 | 0.88% up | 22% up | ||
| 24 | Mirum PharmaceuticalsMIRM · Health Care | 12.3 | CZK 142.3B | CZK 2,179.26 | 2.47% up | 35% up | ||
| 25 | TG TherapeuticsTGTX · Health Care | 15.8 | CZK 217B | CZK 1,435.62 | 0.63% down | 103% up | ||
| 26 | Royalty PharmaRPRX · Health Care | 16.6 | CZK 878.1B | CZK 1,527.14 | 1.27% up | 74% up | ||
| 27 | Eli LillyLLY · Health Care | 18.5 | CZK 26.89T | CZK 30,188.73 | 0.34% up | 28% up | ||
| 28 | Ligand PharmaceuticalsLGND · Health Care | 21.5 | CZK 128.1B | CZK 6,405.06 | 0.24% up | 44% up | ||
| 29 | BridgeBio PharmaBBIO · Health Care | 30.0 | CZK 335.1B | CZK 1,720.20 | 1.19% down | 15% up | ||
| 30 | Rhythm PharmaceuticalsRYTM · Health Care | 41.4 | CZK 175B | CZK 2,524.52 | 2.94% down | 15% up | ||
| 31 | InsmedINSM · Health Care | 52.5 | CZK 708.7B | CZK 3,230.64 | 0.43% up | 27% down | ||
| 32 | CytokineticsCYTK · Health Care | 82.0 | CZK 160.8B | CZK 1,154.15 | 0.72% up | 21% down | ||
| 33 | Protagonist TherapeuticsPTGX · Health Care | 174 | CZK 178.1B | CZK 2,727.94 | 1.22% down | 45% up | ||
| 34 | Dianthus TherapeuticsDNTH · Health Care | 2334 | CZK 105.8B | CZK 1,878.75 | 0.54% down | 105% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2680 CZK). 10 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies in the United States have the lowest P/S ratio?
Viatris (1.6), Amneal Pharmaceuticals (2.4) and Pfizer (2.5) have the lowest P/S ratio of the 34 pharmaceutical companies in the United States ranked here as of 20 Nov 2026, 16:40 UTC.
How many pharmaceutical companies in the United States are in this ranking?
34 are ranked by P/S ratio. 10 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies in the United States worth together?
The 34 pharmaceutical companies in the United States ranked by P/S ratio have a combined market value of CZK 83.87T as of 20 Nov 2026, 16:40 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies in the United States by P/S ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.